Citation Impact
Citing Papers
Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti–human DEC205 monoclonal antibody
2010 StandoutNobel
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation
2017
Cross-Priming as a Predominant Mechanism for Inducing CD8+ T Cell Responses in Gene Gun DNA Immunization
2001
Immunogenicity of Whole-Parasite Vaccines against Plasmodium falciparum Involves Malarial Hemozoin and Host TLR9
2010
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses
2001
EX VIVO GENERATION OF EFFECTIVE EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES FROM THE PERIPHERAL BLOOD OF IMMUNOCOMPETENT EPSTEIN BARR VIRUS-SERONEGATIVE INDIVIDUALS1
2000
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
1999
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pattern Recognition Receptors and Inflammation
2010 Standout
Structure of Dengue Virus
2002 Standout
Mechanism of splenic cell death and host mortality in a Plasmodium yoelii malaria model
2017
New horizons in adjuvants for vaccine development
2020
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection
2011
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity
2015
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
2008
Taming cancer by inducing immunity via dendritic cells
2007
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Dendritic cells in cancer immunotherapy
2010
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
New horizons in adjuvants for vaccine development
2008
Immunity, Inflammation, and Cancer
2010 Standout
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Antigens for cancer immunotherapy
2008
Epstein–Barr virus: 40 years on
2004 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
LAG-3 in Cancer Immunotherapy
2010
Contrasting Roles of Dendritic Cells and B Cells in the Immune Control of Epstein-Barr Virus
2003
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
2008 StandoutNobel
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
Infection in Solid-Organ Transplant Recipients
2007 Standout
Immune escape by Epstein–Barr virus associated malignancies
2008
Interferon-γ: The Jekyll and Hyde of Malaria
2015
DNA and RNA-based vaccines: principles, progress and prospects
1999
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
2007
Epstein–Barr Virus Infection
2000 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
A Re-Evaluation of the Frequency of CD8+ T Cells Specific for EBV in Healthy Virus Carriers
1999
A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells
2006
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology
2020 StandoutNobel
Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated Diseases
2000
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34 + Cells with Epstein-Barr Virus
2004
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
2006 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
2003 StandoutNobel
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
2011 StandoutNobel
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells
2007
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
2004
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
2011 StandoutNobel
HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
1997
Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves
2009 StandoutNobel
Clonal Expansions in Acute EBV Infection Are Detectable in the CD8 and not the CD4 Subset and Persist with a Variable CD45 Phenotype
2000
EBV-Specific CD8+ T Cell Memory: Relationships Between Epitope Specificity, Cell Phenotype, and Immediate Effector Function
2001
Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)
2006
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes
2004
CD8+ T-cell selection, function, and death in the primary immune response in vivo
2000
Vaccines to Prevent Infections by Oncoviruses
2010
The BZLF1 Homolog of an Epstein-Barr-Related γ-Herpesvirus Is a Frequent Target of the CTL Response in Persistently Infected Rhesus Macaques
2006
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles
2002
A Virus-Like Particle-Based Epstein-Barr Virus Vaccine
2011
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
Post-Transplant Lymphoproliferative Disorders
2004
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001 StandoutNobel
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice
2021 StandoutNobel
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8+T-Cell Immunity
2002
Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells
2005
Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
2011 StandoutNobel
Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients
2001
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp100
2000
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
1992 Standout
Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals
2002
Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus
2007
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Works of Suzanne Elliott being referenced
An HLA-A2 Polyepitope Vaccine for Melanoma Immunotherapy
1999
A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs
2011
Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis.
1996
Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy
2003
Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines
2000
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum
2002
Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems
1999
Dominant Cytotoxic T Lymphocyte Response to the Immediate‐EarlyTrans‐ Activator Protein, BZLF1, in Persistent Type A or B Epstein‐Barr Virus Infection
1997
Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine
2003
Strategies Involved in Developing an Effective Vaccine for EBV-Associated Diseases
1996
Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: Implications for molecular mimicry in autoimmune disease
1999
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
1999
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
2006
Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis
2007
Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load
2001
Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720)
1995
Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination
1998
Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD8+Cytotoxic T-Cell Epitopes
1999